Bortezomib in mantle cell lymphoma: comparative therapeutic outcomes

References

• DreylingMGeislerCHermineOESMO Guidelines Working GroupNewly diagnosed and relapsed mantle cell lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-upAnn Oncol201425suppl 3iii83iii9225210087
   PubMed Web of Science ®Google Scholar
• SmithACrouchSLaxSLymphoma incidence, survival and prevalence 2004–2014: sub-type analyses from the UK’s Haematological Malignancy Research NetworkBr J Cancer201511291575158425867256
   PubMed Web of Science ®Google Scholar
• WangYMaSRacial differences in mantle cell lymphoma in the United StatesBMC Cancer20141476425315847
   PubMed Web of Science ®Google Scholar
• ArgatoffLHConnorsJMKlasaRJHorsmanDEGascoyneRDMantle cell lymphoma: a clinicopathologic study of 80 casesBlood1997896206720789058729
   PubMed Web of Science ®Google Scholar
• MartinPChadburnAChristosPOutcome of deferred initial therapy in mantle-cell lymphomaJ Clin Oncol20092781209121319188674
   PubMed Web of Science ®Google Scholar
• FernàndezVSalameroOEspinetBGenomic and gene expression profiling defines indolent forms of mantle cell lymphomaCancer Res20107041408141820124476
   PubMed Web of Science ®Google Scholar
• NavarroAClotGRoyoCMolecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical featuresCancer Res201272205307531622915760
   PubMed Web of Science ®Google Scholar
• MartinPLeonardJIs there a role for “watch and wait” in patients with mantle cell lymphoma?Semin Hematol201148318919321782061
   PubMed Web of Science ®Google Scholar
• HosterEDreylingMKlapperWGerman Low Grade Lymphoma Study Group (GLSG), European Mantle Cell Lymphoma NetworkA new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphomaBlood2008111255856517962512
   PubMed Web of Science ®Google Scholar
• SchulzHBohliusJFTrelleSImmunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysisJ Natl Cancer Inst200799970671417470738
   PubMed Web of Science ®Google Scholar
• GriffithsRMikhaelJGleesonMDaneseMDreylingMAddition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphomaBlood2011118184808481621873544
   PubMed Web of Science ®Google Scholar
• HosterEMetznerBForstpointnerRAutologous stem cell transplantation and addition of rituximab independently prolong response duration in advanced stage mantle cell lymphomaASH Annu Meet Abstr200911422880
   Google Scholar
• Kluin-NelemansHCHosterEHermineOTreatment of older patients with mantle-cell lymphomaN Engl J Med2012367652053122873532
   PubMed Web of Science ®Google Scholar
• LenzGDreylingMHosterEImmunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)J Clin Oncol20052391984199215668467
   PubMed Web of Science ®Google Scholar
• HermineOHosterEWalewskiJAlternating courses of 3× CHOP and 3× DHAP plus rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) increases overall survival when compared to 6 courses of CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: final analysis of the MCL younger trial of the European Mantle Cell Lymphoma Network (MCL net)ASH Annu Meet Abstr201212021151
   Google Scholar
• RomagueraJEFayadLEFengLTen-year follow-up after intense chemoimmunotherapy with rituximab-HyperCVAD alternating with rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphomaBr J Haematol2010150220020820528872
   PubMed Web of Science ®Google Scholar
• MerliFLuminariSIlariucciFRituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio LinfomiBr J Haematol2012156334635322145911
   PubMed Web of Science ®Google Scholar
• BernsteinSHEpnerEUngerJMA phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213Ann Oncol20132461587159323504948
   PubMed Web of Science ®Google Scholar
• RummelMJNiederleNMaschmeyerGStudy Group Indolent Lymphomas (STIL)Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trialLancet201338198731203121023433739
   PubMed Web of Science ®Google Scholar
• FlinnIWvan der JagtRKahlBSRandomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT studyBlood2014123192944295224591201
   PubMed Web of Science ®Google Scholar
• RobakTHuangHJinJLYM-3002 InvestigatorsBortezomib-based therapy for newly diagnosed mantle-cell lymphomaN Engl J Med20153721094495325738670
   PubMed Web of Science ®Google Scholar
• BauwensDMaerevoetMMichauxLActivity and safety of combined rituximab with chlorambucil in patients with mantle cell lymphomaBr J Haematol2005131333834016225653
   PubMed Web of Science ®Google Scholar
• SachanasSPangalisGAVassilakopoulosTPCombination of rituximab with chlorambucil as first line treatment in patients with mantle cell lymphoma: a highly effective regimenLeuk Lymphoma201152338739321133713
   PubMedGoogle Scholar
• ColemanMMartinPRuanJLow-dose metronomic, multidrug therapy with the PEP-C oral combination chemotherapy regimen for mantle cell lymphomaLeuk Lymphoma200849344745018297520
   PubMed Web of Science ®Google Scholar
• MorschhauserFACartronGThieblemontCObinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN studyJ Clin Oncol201331232912291923835718
   PubMed Web of Science ®Google Scholar
• FurtadoMDyerMJJohnsonRBerrowMRuleSOfatumumab monotherapy in relapsed/refractory mantle cell lymphoma – a phase II trialBr J Haematol2014165457557824666179
   PubMed Web of Science ®Google Scholar
• WangMLRuleSMartinPTargeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphomaN Engl J Med2013369650751623782157
   PubMed Web of Science ®Google Scholar
• MaddocksKChristianBJaglowskiSA phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphomaBlood2015125224224825355819
   PubMed Web of Science ®Google Scholar
• GoyABernsteinSHKahlBSBortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE studyAnn Oncol200920352052519074748
   PubMed Web of Science ®Google Scholar
• GoyASinhaRWilliamsMESingle-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) studyJ Clin Oncol201331293688369524002500
   PubMed Web of Science ®Google Scholar
• HessGHerbrechtRRomagueraJPhase III study to evaluate temsirolimus compared with investigator’s choice therapy for the treatment of relapsed or refractory mantle cell lymphomaJ Clin Oncol200927233822382919581539
   PubMed Web of Science ®Google Scholar
• TrnenyMLamyTWalewskiJASubgroup analysis of the phase II randomized MCL-002 (SPRINT) study of lenalidomide vs investigator’s choice in relapsed/refractory mantle cell lymphomaASCO Meet Abstr20153315 suppl8547
   Google Scholar
• WangYDela RosaMLZhouSLenalidome in combination with rituximab for relapsed or refractory mantel cell lymphoma: updated analysis of a phase 2 trialASCO Meet Abstr20153315 suppl8542
   Google Scholar
• KahlBByrdJCFlinnIWClinical safety and activity in a phase 1 study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110{delta}, in patients with relapsed or refractory non-Hodgkin lymphomaASH Annu Meet Abstr2010116211777
   Google Scholar
• MujtabaTDouQPAdvances in the understanding of mechanisms and therapeutic use of bortezomibDiscov Med2011126747148022204764
   PubMed Web of Science ®Google Scholar
• SpataroVNorburyCHarrisALThe ubiquitin-proteasome pathway in cancerBr J Cancer19987734484559472642
   PubMed Web of Science ®Google Scholar
• AdamsJThe proteasome: structure, function, and role in the cellCancer Treat Rev200329suppl 13912738238
   PubMed Web of Science ®Google Scholar
• PaganoMTamSWTheodorasAMRole of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27Science199526952246826857624798
   PubMed Web of Science ®Google Scholar
• PaoluzziLO’ConnorOAMechanistic rationale and clinical evidence for the efficacy of proteasome inhibitors against indolent and mantle cell lymphomasBioDrugs2006201132316573348
   PubMed Web of Science ®Google Scholar
• MitsiadesNMitsiadesCSPoulakiVMolecular sequelae of proteasome inhibition in human multiple myeloma cellsProc Natl Acad Sci U S A20029922143741437912391322
   PubMed Web of Science ®Google Scholar
• PalombellaVJRandoOJGoldbergALManiatisTThe ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa BCell19947857737858087845
   PubMed Web of Science ®Google Scholar
• QinJZZiffraJStennettLProteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cellsCancer Res200565146282629316024630
   PubMed Web of Science ®Google Scholar
• LandowskiTHMegliCJNullmeyerKDLynchRMDorrRTMitochondrial-mediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell linesCancer Res20056593828383615867381
   PubMed Web of Science ®Google Scholar
• AlinariLWhiteVLEarlCTCombination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphomaMAbs200911314020046572
   PubMed Web of Science ®Google Scholar
• BaiocchiRAAlinariLLustbergMEPhase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphomaCancer2011117112442245124048792
   PubMed Web of Science ®Google Scholar
• CzuczmanMSOlejniczakSGowdaAAcquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levelsClin Cancer Res20081451561157018316581
   PubMed Web of Science ®Google Scholar
• WangMHanXHZhangLBortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivoLeukemia200822117918517898787
   PubMed Web of Science ®Google Scholar
• MoreauPKaramaneshtIIDomnikovaNPharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myelomaClin Pharmacokinet2012511282382923018466
   PubMed Web of Science ®Google Scholar
• LealTBRemickSCTakimotoCHDose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a national cancer institute organ dysfunction working group studyCancer Chemother Pharmacol20116861439144721479634
   PubMed Web of Science ®Google Scholar
• LoRussoPMVenkatakrishnanKRamanathanRKPharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI organ dysfunction working group study NCI-6432Clin Cancer Res201218102954296322394984
   PubMed Web of Science ®Google Scholar
• O’ConnorOAWrightJMoskowitzCPhase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin’s lymphoma and mantle cell lymphomaJ Clin Oncol200523467668415613699
   PubMed Web of Science ®Google Scholar
• GoyAYounesAMcLaughlinPPhase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin’s lymphomaJ Clin Oncol200523466767515613697
   PubMed Web of Science ®Google Scholar
• BelchAKouroukisCTCrumpMA phase II study of bortezomib in mantle cell lymphoma: the national cancer institute of Canada clinical trials group trial IND.150Ann Oncol200718111612116971665
   PubMed Web of Science ®Google Scholar
• KouroukisCTFernandezLACrumpMA phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the national cancer institute of Canada clinical trials group (IND 172)Leuk Lymphoma201152339439921323520
   PubMed Web of Science ®Google Scholar
• LammWKaufmannHRadererMBortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphomaHaematologica20119671008101421486866
   PubMed Web of Science ®Google Scholar
• FriedbergJWVoseJMKellyJLThe combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphomaBlood2011117102807281221239695
   PubMed Web of Science ®Google Scholar
• HowardOMGribbenJGNeubergDSRituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survivalJ Clin Oncol20022051288129411870171
   PubMed Web of Science ®Google Scholar
• RuanJMartinPFurmanRRBortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphomaJ Clin Oncol201129669069721189393
   PubMed Web of Science ®Google Scholar
• RichardsonPGBarlogieBBerensonJA phase 2 study of bortezomib in relapsed, refractory myelomaN Engl J Med2003348262609261712826635
   PubMed Web of Science ®Google Scholar
• JagannathSBarlogieBBerensonJA phase 2 study of two doses of bortezomib in relapsed or refractory myelomaBr J Haematol2004127216517215461622
   PubMed Web of Science ®Google Scholar
• MateosMVRichardsonPGSchlagRBortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trialJ Clin Oncol201028132259226620368561
   PubMed Web of Science ®Google Scholar
• ChangJEPetersonCChoiSVcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin oncology network studyBr J Haematol2011155219019721848883
   PubMed Web of Science ®Google Scholar
• KahlBSLongoWLEickhoffJCWisconsin Oncology NetworkMaintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin oncology networkAnn Oncol20061791418142316766582
   PubMed Web of Science ®Google Scholar
• ChangJELiHSmithMRPhase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern cooperative oncology group study (E1405)Blood2014123111665167324458437
   PubMed Web of Science ®Google Scholar
• HouotRLe GouillSOjeda UribeMFrench GOELAMS GroupCombination of rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RiPAD+C) as first-line therapy for elderly mantle cell lymphoma patients: results of a phase II trial from the GOELAMSAnn Oncol20122361555156122012966
   PubMed Web of Science ®Google Scholar
• TillBGLiHBernsteinSHPhase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for previously untreated mantle cell lymphoma: SWOG 0601ASH Annu Meet201412421149
   Google Scholar
• DamonLEJohnsonJLNiedzwieckiDImmunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909J Clin Oncol200927366101610819917845
   PubMed Web of Science ®Google Scholar
• KaplanLJungSBarteletNBortezomib maintenance (BM) versus consolidation (BC) following aggressive immunochemotherapy and autologous stem cell transplant (ASCT) for untreated mantle cell lymphoma (MCL): CALGB 50403Hematol Oncol201331S1126
   Google Scholar
• DreylingMLenzGHosterEEarly consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL NetworkBlood200510572677268415591112
   PubMed Web of Science ®Google Scholar
• van ‘t VeerMBde JongDMacKenzieMHigh-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patientsBr J Haematol2009144452453019036081
   PubMed Web of Science ®Google Scholar
• GeislerCHKolstadALaurellANordic Lymphoma GroupLong-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma GroupBlood200811272687269318625886
   PubMed Web of Science ®Google Scholar
• DelarueRHaiounCRibragVGroupe d’Etude des Lymphomes de l’Adulte (GELA)CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d’Etude des Lymphomes de l’AdulteBlood20131211485322718839
   PubMed Web of Science ®Google Scholar
• RomagueraJEFayadLRodriguezMAHigh rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabineJ Clin Oncol200523287013702316145068
   PubMed Web of Science ®Google Scholar
• InwardsDJFishkinPAHillmanDWLong-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North central cancer treatment groupCancer2008113110811618470909
   PubMed Web of Science ®Google Scholar
• FenskeTSShahNMKimKMA phase 2 study of weekly temsirolimus and bortezomib for relapsed or refractory B-cell non-Hodgkin lymphoma: a Wisconsin oncology network studyCancer2015121193465347126079295
   PubMed Web of Science ®Google Scholar